Bevacizumab, Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

Sponsor
Eastern Cooperative Oncology Group
Study ID
NCT00387699
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • bevacizumab — BIOLOGICAL
  • cisplatin — DRUG
  • etoposide — DRUG
  • radiation therapy — RADIATION

Study Details

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some find tumor cells and help kill them or carry tumor-killing substances to them. Others interfere with the ability of tumor cells to grow and spread. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy, such as cisplatin and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving bevacizumab together with cisplatin, etoposide, and radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving bevacizumab together with cisplatin, etoposide, and radiation therapy works in treating patients with limited-stage small cell lung cancer.

Key Dates

First listed
Oct 13, 2006
Start date
Oct 31, 2006
Status verified
Oct 2008
Primary completion
Oct 31, 2007
Completion
Apr 30, 2014

Study Design

Enrollment
79 participants (estimated)
Primary purpose
TREATMENT

Primary Outcome Measure

Progression-free survival at 1 year

Related Studies